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MThomasPrimary Care and Population Sciences, Faculty of Medicine, University of Southampton.@ERSpublications: Well-designed non-pharmacological interventions can harnesstreatment responses seen in the placebo arm.
We read with interest the piece by Pattinson and Wanigaseraka [1], discussing theclinical implications of the recent trial by Currow et al. [2], which demonstrated paritybetween sertraline and placebo for improving breathlessness intensity. In particular,Pattinson and Wanigaseraka noted that differential response expectations canpotentially confound outcomes between otherwise balanced intervention vs. placebo-controlled groups. Such expectations have clinical implications: the management ofresponse expectations should be examined and potentially harnessed to improvetreatment outcomes for patients with chronic breathlessness, as suggested bySimilowski and Serresse [3].In his excellent paper, Turner [4] reiterated that a placebo-controlled trial (PCT)compares a particular component of a treatment (often primarily pharmacological)while attempting to keep all other therapeutically-relevant components identical.Ideally, such an approach precludes bias and is the gold-standard to develop evidence-based medical treatments. However, chronic breathlessness (amongst other complexlong-term conditions) is increasingly recognised as dysfunction across multipleinterconnected systems. As such it requires holistic treatment that, alongsidephysiological factors, addresses social, psychological, neurocognitive and behaviouralaspects of disease. Therefore, it must be acknowledged that although PCTs are designedto examine one specific treatment component, multiple components will impact patientoutcomes – and these components may be present in both the treatment and placebogroup.This issue is particularly relevant in respiratory research, in which studies haveconsistently demonstrated very limited associations between objective physiologicalimpairment and the subjective perceptions of breathlessness severity [5,6]. Thus,treatment benefits may impact patients through a diverse and complex interacting setof mechanisms (such as neurocognitive predispositions towards subjective symptomseverity, as suggested by Ongaro and Kaptchuk [7]) which Pattinson and Wanigaserakarightly note may not be balanced between PCT trial arms. Pertinently, we do not wish todevalue ‘traditional’ RCTs. However, evidence from such trials should be consideredalongside other types of research methods, such as ‘pragmatic’ research that more
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closely reflects routine clinical care and ‘additively’ evaluates the incorporation of a newtreatment to a patients’ existing care, carefully monitoring all aspects of the newtreatment (e.g. interaction with healthcare, subsequent self-management) in order tounderstand the likely mechanisms by which treatment benefits are conferred.Many medical professionals think of a ‘placebo’ as an inert pill but, as Turner noted, acomparison with ‘placebo’ in a trial is merely a comparison of one group with another –and the ‘placebo pill’ is merely a symbolic object involved in this process. This processdefinition is in line with modern accounts of clinical placebos focussed on context,meaning and embodiment. We also agree with Pattinson and Wanigaseraka’s point that‘placebo’ is often used disparagingly to refer to treatments that do not work; such aposition risks overlooking the benefits that are conferred independently to identifiedphysiological improvements. This is particularly relevant for non-pharmacologicaltreatments such as breathing retraining exercises, mindfulness-based treatments orcognitive behavioural therapy, which are increasingly used as effective patienttreatments in respiratory disease but demonstrate no measurable effect onphysiological outcomes. By defining placebos as ‘inert’ substances we are in danger ofclassifying such complementary treatments as ineffective, when in fact they may becost-effective adjunct treatments that offer tangible patient benefits.We welcome the call for ‘open-label’ placebo research. However, a considered andcautious approach should be taken, insofar as such treatment may merely demonstratethe presence of broad psychological and behavioural treatment effects withoutdetermining which of these can be targeted (and therefore impacted by well-designednon-pharmacological interventions). Moreover, as Currow[8] notes (supported bymodern contextual accounts of the placebo phenomenon[9]), although the results ofsmall-scale open-label placebo trials may reflect genuine therapeutic benefit, they mayalso just be an artefact of the experimental situation – meaning it is unclear how such atreatment reponse can be harnessed.These effects of open-label placebos are not caused by the ‘inert’ pill itself, but by theconstruction and exploitation of a whole treatment process. Given that many existingnon-pharmacological interventions can be conceived of as already established wholetreatment processes (without the negative connotations of placebos) we advocate thatthe best way to therapeutically employ beneficial treatment responses may be toconduct careful research on these non-pharmacological interventions.
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